764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors
oleh: Benjamin Thompson, Li Yao, Yana G Najjar, Siwen Hu-Lieskovan, Raphael Clynes, Bartosz Chmielowski, Mark N Stein, Sarina A Piha-Paul, Patricia McGovern, Judy S Wang, Benjamin Garmezy, Manojkumar Bupathi, Jitendra Kanodia
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2023-11-01 |
Deskripsi
No description available for this item.